Evoke Pharma Inc. (NASDAQ:EVOK) fell 2.7% on Thursday . The stock traded as low as $10.02 and last traded at $10.60, with a volume of 95,574 shares traded. The stock had previously closed at $10.89.

Several research firms have recently weighed in on EVOK. Rodman & Renshaw reissued a “buy” rating and set a $27.00 price objective on shares of Evoke Pharma in a research note on Monday. FBR & Co reissued a “buy” rating on shares of Evoke Pharma in a research note on Friday, July 8th. Brean Capital reissued a “buy” rating on shares of Evoke Pharma in a research note on Friday, July 8th. Zacks Investment Research lowered Evoke Pharma from a “buy” rating to a “hold” rating in a research note on Monday, May 16th. Finally, Northland Securities began coverage on Evoke Pharma in a research note on Wednesday, March 16th. They set an “outperform” rating and a $16.00 price objective for the company. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $17.47.

The firm’s 50-day moving average is $6.47 and its 200-day moving average is $4.71. The company’s market cap is $75.73 million.

Evoke Pharma (NASDAQ:EVOK) last issued its earnings results on Wednesday, May 11th. The specialty pharmaceutical company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.41) by $0.04. Equities research analysts anticipate that Evoke Pharma Inc. will post ($1.37) EPS for the current year.

In related news, major shareholder Parters Vii L. P. Domain sold 5,095 shares of the company’s stock in a transaction on Wednesday, April 27th. The shares were sold at an average price of $5.07, for a total value of $25,831.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Parters Vii L. P. Domain sold 41,478 shares of the company’s stock in a transaction on Wednesday, April 20th. The shares were sold at an average price of $5.35, for a total transaction of $221,907.30. The disclosure for this sale can be found here.

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.